Understanding and treating genetic changes in metastatic breast cancer
Official title: Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-10902114 · Data updated 2026-11-12
This study is looking at how certain genetic changes in metastatic breast cancer, especially those caused by the APOBEC enzyme, might make the cancer harder to treat, and it’s for patients who want to learn more about their cancer and how to get the best treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 13, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $445,626 |
| NIH project number | 5P50CA247749-05 |
| Project ID | NIH-10902114 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with metastatic estrogen receptor-positive breast cancer who have shown resistance to standard endocrine therapies.
✕Less likely to help
Patients with early-stage breast cancer or those whose cancer is not estrogen receptor-positive may not benefit from this research.
What this research studies
This research investigates the role of specific genetic mutations, particularly those caused by the APOBEC enzyme, in metastatic breast cancer. By analyzing the differences between primary and metastatic tumors, the study aims to identify how these mutations contribute to resistance against standard treatments. Patients may undergo genomic analyses to help determine the presence of these mutations, which could inform more effective treatment strategies tailored to their specific cancer profile.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic breast cancer, improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results in understanding mutational signatures in cancer, suggesting that this approach could yield valuable insights and advancements in treatment.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chandarlapaty, Sarat — Sloan-Kettering Inst Can Research
- Study coordinator: Chandarlapaty, Sarat
Related research
Other NIH-funded projects on the same topics.
-
Understanding FGFR1-amplified breast cancer to overcome endocrine resistance
This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.
-
Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer
A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.
-
Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active
A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.
-
Acupuncture to ease symptoms for people with metastatic breast cancer
A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.
-
Predicting end-of-life timing to guide better care for metastatic breast cancer
A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.
-
Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer
A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.